Eikon Therapeutics, Inc.
EIKN
$8.77
-$0.21-2.34%
NASDAQ
| 03/31/2026 | 12/31/2025 | 03/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 17.29M | 17.73M | 14.80M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 87.34M | 82.96M | 71.38M | ||
| Operating Income | -87.34M | -82.96M | -71.38M | ||
| Income Before Tax | -82.96M | -79.66M | -68.24M | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -82.96M | -79.66M | -68.24M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -82.96M | -79.66M | -68.24M | ||
| EBIT | -87.34M | -82.96M | -71.38M | ||
| EBITDA | -82.12M | -77.57M | -67.59M | ||
| EPS Basic | -2.46 | -26.38 | -26.91 | ||
| Normalized Basic EPS | -1.54 | -16.44 | -15.40 | ||
| EPS Diluted | -2.46 | -26.38 | -26.91 | ||
| Normalized Diluted EPS | -1.54 | -16.44 | -15.40 | ||
| Average Basic Shares Outstanding | 33.70M | 3.02M | 2.77M | ||
| Average Diluted Shares Outstanding | 33.70M | 3.02M | 2.77M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||